Efficacy of 23-valent pneumococcal polysaccharide vaccine in preventing community-acquired pneumonia among immunocompetent adults: A systematic review and meta-analysis of randomized trials

Highlights • Our aim is to study efficacy of PPV-23 against CAP other than other PPV valences. • PPV-23 can prevent all-cause pneumonia among immunocompetent adults. • It has greater efficacy against CAP among the targeted population. • It shows protective trends for pneumococcal pneumonia and morta...

Full description

Saved in:
Bibliographic Details
Published inVaccine Vol. 34; no. 13; pp. 1496 - 1503
Main Authors Diao, Wen-qi, Shen, Ning, Yu, Pan-xi, Liu, Bei-bei, He, Bei
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Ltd 18.03.2016
Elsevier Limited
Subjects
23-Valent pneumococcal polysaccharide vaccine
Adult
Aged
Aged, 80 and over
Allergy and Immunology
Chronic obstructive pulmonary disease
Community-Acquired Infections - prevention & control
Community-acquired pneumonia
Efficacy
Health Services Needs and Demand
Humans
Immunization
Immunocompetent
Meta-analysis
Middle Aged
Mortality
Pneumococcal Vaccines - therapeutic use
Pneumonia
Pneumonia, Pneumococcal - prevention & control
Randomized Controlled Trials as Topic
Vaccines
Young Adult
Efficacy
Community-acquired pneumonia
Immunocompetent
23-Valent pneumococcal polysaccharide vaccine
Meta-analysis
Online AccessGet full text

Cover

More Information
Summary:Highlights • Our aim is to study efficacy of PPV-23 against CAP other than other PPV valences. • PPV-23 can prevent all-cause pneumonia among immunocompetent adults. • It has greater efficacy against CAP among the targeted population. • It shows protective trends for pneumococcal pneumonia and mortality from pneumonia. • It does not prevent all-cause mortality.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-Review-4
content type line 23
ObjectType-Undefined-3
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2016.02.023